Cited by 21Diabetes Management and ResearchDementia and Cognitive Impairment ResearchNeurological and metabolic disorders

Effect of Hypoglycemia on Brain Structure in People With Type 2 Diabetes: Epidemiological Analysis of the ACCORD-MIND MRI Trial

Open access
Zhang, Zi, Lovato, James, Battapady, Harsha, Davatzikos, Christos, Gerstein, Hertzel C., Ismail-Beigi, Faramarz, Launer, Lenore J., Murray, Anne +5 more·2014·Diabetes Care

Abstract

OBJECTIVE: The effect of hypoglycemia related to treatment of type 2 diabetes mellitus (T2DM) on brain structure remains unclear. We aimed to assess whether symptomatic severe hypoglycemia is associated with brain atrophy and/or white matter abnormalities. RESEARCH DESIGN AND METHODS: We included T2DM participants with brain MRI from the Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) trial. Symptomatic severe hypoglycemia was defined as blood glucose <2.8 mmol/L or symptoms resolved with treatments that required the assistance of another person or medical assistance (hypoglycemia requiring assistance [HA]). Standardized brain MRI was performed at baseline and at 40 months. Total brain volume (TBV) and abnormal white matter (AWM) volume were calculated using an automated computer algorithm. Brain MRI scans of hypoglycemic participants were also reviewed for local disease. RESULTS: Of the 503 T2DM participants (mean age, 62 years) with successful baseline and 40-month brain MRI, 28 had at least one HA episode during the 40-month follow-up. Compared with participants without HA, those with HA had marginally significant less atrophy (less decrease in TBV) from baseline to 40 months (−9.55 [95% CI −15.21, −3.90] vs. −15.38 [95% CI −16.64, −14.12], P = 0.051), and no significant increase of AWM volume (2.06 [95% CI 1.71, 2.49] vs. 1.84 [95% CI 1.76, 1.91], P = 0.247). In addition, no unexpected local signal changes or volume loss were seen on hypoglycemic participants’ brain MRI scans. CONCLUSIONS: Our study suggests that hypoglycemia related to T2DM treatment may not accentuate brain pathology, specifically brain atrophy or white matter abnormalities.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc14-0973

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Lowered cognitive performance appears to be more associated with the presence of microvascular complications or poor metabolic control than with the occurrence of severe hypoglycemic episodes.

    “Lowered cognitive performance appears to be more associated with the presence of microvascular complications or poor metabolic control than with the occurrence of severe hypoglycemic episodes (57,61).”

    From Hypoglycemia (2018) · cites this paper as [57]

    The Conclusions (page unavailable) report no additional brain atrophy or abnormal white matter after severe symptomatic hypoglycemia in treated people with type 2 diabetes, which offers indirect support for the hypoglycemia part of the claim. But the paper measures brain structure, not cognitive performance, and does not establish that microvascular complications or poor metabolic control are more strongly associated with lowered cognitive performance. It explicitly cautions that its MRI measures reflect structure, not function. (LLM, conf=0.82)

    Experimental — accuracy not yet measured
  • Prospective studies have not found an association between intensive insulin therapy and cognitive function, or between severe hypoglycemia and future cognitive function.

    “Prospective studies have not found an association between intensive insulin therapy and cognitive function (58)(59)(60), or between severe hypoglycemia and future cognitive function (56,57).”

    From Hypoglycemia (2018) · cites this paper as [57]

    The Introduction (page not provided) reports that the DCCT found no significant correlation between treatment-related hypoglycemic events and neuropsychological function. But this paper’s own prospective analysis measured brain structure, not future cognitive function; the Conclusions explicitly caution that its MRI variables reflect structure, not function. It therefore does not establish the claimed lack of association between severe hypoglycemia and future cognitive function. (LLM, conf=0.83)

    Experimental — accuracy not yet measured
  • The person with cognitive disorders is at high risk of future severe hypoglycemic episodes, possibly because of medication errors.

    “The person with cognitive disorders is at high risk of future severe hypoglycemic episodes, possibly because of medication errors (19,56,57)”

    From Hypoglycemia (2018) · cites this paper as [57]

    The Introduction discusses severe hypoglycemia as a possible antecedent of cognitive impairment, not cognitive disorders as a predictor of future episodes. The Results and Conclusions identify other factors associated with hypoglycemia, but do not establish increased risk from cognitive disorders or mention medication errors (searched: future episodes, cognitive impairment, medication errors). (LLM, conf=0.72)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 43 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Zhang, Z., Lovato, J., Battapady, H., Davatzikos, C., Gerstein, H. C., Ismail-Beigi, F., Launer, L. J., Murray, A., Punthakee, Z., Tirado, A. A., Williamson, J., Bryan, R. N., & Miller, M. E.
Affiliations
  • University of Pennsylvania (US)
  • Wake Forest University (US)
  • McMaster University (CA)
  • Case Western Reserve University, Cleveland, OH
  • National Institutes of Health (US)
  • Hennepin County Medical Center (US)
  • Columbia University (US)
Corresponding author
Bryan, R. Nick
Venue
Diabetes Care
Published
2014-11-08
Volume
37
Issue
12
Pages
3279-3285
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2078416668
Cited by
20
References
43
Citations by year
2025: 1 · 2024: 1 · 2023: 1 · 2022: 1 · 2019: 1 · 2018: 4 · 2017: 3 · 2016: 5 · 2015: 3
FWCI
2.95
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (n01hc95183-23-0-0, n01hc95180-24-0-1, n01hc95184-24-0-1, n01hc95181-23-0-1, n01hc95182-23-0-1, n01hc95178-28-0-1, n01hc95179-25-0-0)
  • National Institute on Aging (AG-0002)
  • National Heart, Lung, and Blood Institute (N01- HC-95181, N01 HC095184, N01-HC- 95180, N01-HC-95178, N01 HC095182, N01 HC095181, N01-HC-095183, N01 HC095178, N01-HC-95184, N01HC95179, N01 HC095180, N01‐HC‐95183, N01-HC-95182, N01 HC095179)
  • National Institute of Biomedical Imaging and Bioengineering (R01EB009234)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Neurological and metabolic disorders
Keywords
hypoglycemia, type 2 diabetes, brain atrophy, white matter abnormalities, total brain volume, brain MRI, diabetes treatment
MeSH terms
Adult, Aged, Atrophy, Blood Glucose, Brain, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Magnetic Resonance Imaging, Male, Memory, Middle Aged, Risk Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review